Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

John F Seymour; Robert Marcus; Andrew Davies; Eve Gallop-Evans; Andrew Grigg; Andrew Haynes; Michael Herold; Thomas Illmer; Herman Nilsson-Ehle; Martin Soekler; Ulrich Duenzinger; Tina Nielsen; Aino Launonen; Wolfgang Hiddemann

Journal article

Association of early disease progression and very poor survival in the GALLIUM study in follicular lymphoma: benefit of obinutuzumab in reducing the rate of early progression

John F Seymour, Robert Marcus, Andrew Davies, Eve Gallop-Evans, Andrew Grigg, Andrew Haynes, Michael Herold, Thomas Illmer, Herman Nilsson-Ehle, Martin Soekler, Ulrich Duenzinger, Tina Nielsen, Aino Launonen, Wolfgang Hiddemann

Haematologica: the hematology journal | FERRATA STORTI FOUNDATION | Published : 2019

DOI: 10.3324/haematol.2018.209015

Download PDF

University of Melbourne Researchers

Andrew Grigg Author Medicine - Austin Health

John Seymour Author Medicine - St Vincent's Hospital

Grants

Funding Acknowledgements

The authors would like to thank all of the patients who participated in the GALLIUM study, and acknowledge all of the study investigators and their staff as well as the GALLIUM study team. Third-party medical writing assistance, under the direction of John Seymour, was provided by Roger Nutter, Scott Malkin and Helen Cathro of Gardiner-Caldwell Communications, and was funded by F. Hoffmann-La Roche Ltd.